Udc 616. 12-009. 72-056. 52-008. 9-092: 612. 018 Adipocytokine changes in patients with stable angina and obesity



Yüklə 90.11 Kb.
tarix01.01.2017
ölçüsü90.11 Kb.
UDC 616.12-009.72-056.52-008.9-092:612.018

ADIPOCYTOKINE CHANGES IN PATIENTS WITH STABLE ANGINA AND OBESITY

Gabisoniia T.N., Kravchun P.P., Pashtiani R.V.

Kharkiv National Medical University, Kharkiv

Department of internal medicine №2, clinical immunology and allergology

The work is part of the research department of internal medicine №2, clinical immunology and allergology Kharkiv National Medical University, Ministry of Health of Ukraine "Neurohumoral effects on the progression of chronic heart failure in patients with hypertension and coronary heart disease with renal dysfunction and anemic syndrome» № state registration 0111U001395.

The most widespread among all cardiovascular diseases is the ischemic heart disease (IHD), which is found in 58% of patients. Despite significant progress in treatment, the prevalence of stable angina grows and reaches 20% among population [3,7].

Obesity is an important risk factor of IHD development. Cardiovascular disorders in patients with obesity are found in the form of systemic atherosclerosis, myocardiodystrophy, arterial hypertension.

The results of the latest research in endocrinology have shown the presence of hormonal activity of adipose tissue and its indirect and direct impact on the body on the whole and on the cardiovascular system in particular [3]. Leptin, adiponectin, visfatin, tumor necrosis factor-α, interleukin-6, interleukin-8 etc. are attributed to the most important active substances which synthesize in adipocytes [2,4,5].

Active scientific research in pathogenic mechanisms of adipose tissue hormones biosynthesis and their role in development of obesity and cardiovascular diseases is performed. The level of adiponectin in patients with obesity is proved to be decreased [9]. М.Kumada et al. have detected the decrease of plasma concentration of this protein in patients with IHD. They foresaw that hypoadiponectinemia could become a new significant risk factor of atherosclerosis and its complications [9].

Visfatin – adipokine, which is produced by visceral adipocytes, is being actively examined. Introduction of recombinant visfatin affects the insulin receptor in the same manner as insulin. The level of visfatin grows in proportion to the level of obesity [1,6]. According to the data provided by Kosygina G.V. the visfatin level of serum is statistically significantly higher in obesity than without it and is correlated with the indices of Total Cholesterol (TC) and cholesterol with low-density lipoproteins (LDL cholesterol) [6]. Maybe this molecule will become the key to the problem of lipid exchange, which is found in patients with obesity [8,10].

This sphere of medical research is challenging and up-to-date, since the acquired data is quite contradictory and requires further study with obtaining new reliable facts, which could become the basis for new diagnostic and therapeutic strategies in metabolic disorders in patients with cardiovascular pathology.

In this connection we have established the objective of research – to define the imbalance of adipocytokines (adiponectin and visfatin) in patients suffering from stable angina and concomitant obesity.



MATERIALS AND METHODS

We examined 110 patients with stable angina (Functional Classes II – III). All patients were divided into 2 groups: 1st group – patients with stable angina with concomitant obesity (n=80), 2nd group – patients with stable angina without obesity (n=30). The average age of the patients suffering from stable angina with concomitant obesity was 66,45±1,08 years old, and of the 2 group - 65,87±1,98. 66 men (60,95%) and 44 women (39,05%) have been examined. The control group comprised 20 practically healthy people which one correspond by age and sex. The patients suffering from stable angina with concomitant acute or chronic inflammatory diseases, renal failure, oncological diseases and insulin dependent diabetes mellitus (IDDM) were not involved in the research.

All patients underwent comprehensive investigation in accordance with the order № 436 of Ministry of Health of Ukraine “Protocols on delivery of health care to the patients with IHD – stable angina”.

Anthropometric measuring included measuring of height, body mass, waist circumference (WC) and hips circumference (HC). For characterizing obesity they used body mass index (BMI), which was determined with the help of the formula: BMI= body mass (kg) / height (m2).

Detection of TC level and high-density lipoproteids (HDL) was realised with the help of peroxidase method using the set of reagents «Cholesterol Liquicolor» («Human» company, Germany) in blood serum, stabilized by heparin and EDTA. The method principle consists in the detection of TC after its enzymic hydrolysis and acidification. The index substance of TC is chilonimin, which is derived from hydrogen dioxode and 4-aminophenazone in the presence of phenol and peroxidase. Chylomicrons, very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL) were deposited by adding phosphoromolybdic acid and magnesium chloride. After centrifugal separation in supernatant high-density lipoproteins (HDL) were left, the level of which was defined with the help of «Cholesterol Liquicolor» kit. The level of high-density lipoproteins HDL <0,9 mmol/l in men and <1,0 mmol/l in women is the criterion for hypoalphacholesterolemia. The level of triglyceride (TG) was defined with the help of enzymic colorimetric method with the use of reagents kit «Triglycerides GPO» («Human», Germany). The method principle consisted in the fact that TG concentration was defined after enzymic hydrolysis under the action of lipase. As a result of the reaction the chilonimin indicator formed with hydrogen dioxide, 4-aminoantipyrine and 4-chlorophenol in catalytic impact of peroxidase. TG level ≥1,7 mmol/l in serum was considered to be a sign of hypertriglyceridemia. The atherogenic index (AI) was calculated according to the formula:AI = (TC – HDL): HDL (mmol/l); VLDL level = TG : 2,2 x 0,45 (mmol/l); LDL level (mmol/l) = TC – (VLDL + HDL).

Adipokines level was defined by the immunoenzymometric methods on the immunoenzymometric analyzer “LabLine-90” (Austria). Adiponectin concentration was defined using the kit produced by «ElisaKit» company (USA). Visfatin concentration was defined using the kit produced by «VisfatinEIAKIT» company (USA).

The statistical processing of results was performed with the help of software package «Statistika» (StaSoftInc, USA). The values calculated: the average (M), dispersion, standard deviation, the median (m), probability and level of significance (p). They used the standard programme of correlation analysis with calculation of average arithmetic means: M+m, σ, probability and level of accuracy (p). Pearson correlation coefficient was used to evaluate the stage between samples (r).

RESULTS AND THEIR DISCUSSING

According to the results of our investigation it was established that statistically in patients from the first group the level of visfatin significantly increase till ( 29,6 ± 2,0 ng/ml) in comparison to the patients from the other group and control group (27,6±1,7 ng/ml ; 19,3 ± 1,3 ng/ml correspondingly). The attention is drawn to significant decrease of adiponectin in patients from the first group ( 5,02 ± 0,22 ng/ml ) in comparison to the second ( 6,02 ± 0,21 ng/ml ) and control group ( 12,45 ±0,15 ng/ml). This indicates that hypoadiponectinemia and hypervisfatinemia are associated with development of obesity in patients with stable angina (Table. 1)

Table 1

Indicators of adipocytokine exchange in patients with stable angina in accordance with occurrence of obesity

(M ± m )

Indicators

Stable angina + obesity

( n=80 )


Stable angina without concomitant obesity ( n=30)

Control group

( n=20)


P

Adiponectin, ng/ml

5,02 ± 0,22

6,02 ± 0,21

12,45 ±0,15

P 1-2 < 0,05

P 1-3 < 0,05

P 2-3 < 0,05


Visfatin, ng/ml

29,6 ± 2,0

27,6±1,7

19,3 ± 1,3

P 1-2 < 0,05

P 1-3 < 0,05

P 2-3 < 0,05

Given that the patients had different body weight, in our opinion, studying the imbalance between adipocytokins in accordance with BMI was very interesting. In this regard the patients were divided into following subgroups: 1st subgroup – patients suffering from stable angina with increased body weight (IBW) (BMI = 28,2±2,1 kg/m2 ) (n= 16), 2nd – patients suffering from stable angina with stage 1 concomitant obesity (BMI = 30,1 ± 1,0 kg/m2 ) ( n=34), 3rd – patients suffering from stable angina with stage 2 concomitant obesity ( BMI = 35,7 ± 1,9 kg/m2 ) ( n= 16) and 4th – patients with stable angina with stage 3 concomitant obesity ( BMI = 40,3 ± 2,1 kg/m2) (n=14).

Table 2

Indices of adipocytokin exchange in accordance with the stage of obesity

( M ± m)

Indices

IBW

(n = 16)


Obesity 1st stage

( n= 34)


Obesity 2nd stage

( n= 16)


Obesity 3rd stage

( n= 14)


Control group

( n= 20)


Adiponectin, ng/ml

5,15±0,17*

5,11±0,22*

5,09±0,38*

4,74± 0,28*

12,4±0,21*

Visfatin, ng/ml

25,1±2,1*

29,7±1,2*

30,0±2,0*

33,6± 2,4*

19,3±1,7*

Note: * Р< 0,05 - in the patient with stable angina depending of body weight and control group;

We observed significant deterioration of adipokine exchange associated with weight gain in patients with stable angina, which was characterized by significant reduction of adiponectin level in patients from the first (5,15±0,17 ng/ml), the second (5,11±0,22 ng/ml), the third (5,09±0,38 ng/ml ), the fourth (4,74± 0,28 ng/ml) subgroups in comparison to control group (12,4±0,21ng/ml). Visfatin level, in its turn, reached 25,1 ng/ml in the first subgroup, 29,7 ng/ml in the second, 30 ng/ml in the third and 33,6 ng/ml in the fourth, which significantly exceeded the levels of this index in control group (19,3±1,7ng/ml ). Taking into account the above mentioned it is possible to say that a progression of atherosclerosis in patients with stable angina by way of exhaustion of antiatherogenic capabilities of adiponectin accompanied by activation of lipid disorders in patients with concomitant obesity with the help of visfatin.

The results of correlation analysis have shown that there are statistically significant ties practically between all indices of lipid and adipokine exchange. Thus direct correlation ties have been found in patients between visfatin and BMI ( r = 0,46; P< 0,05); between visfatin and AI (r=0,58; Р<0,05); VLDL and visfatin ( r = 0,53;P< 0,05); LDL and visfatin ( r = 0,61;P< 0,05); TG and visfatin ( r = 0,48;P< 0,05), inverse correlation relationship was established between visfatin and HDL (r = - 0,54; Р<0,05), which shows that in patients suffering from stable angina with concomitant obesity together with growth of BMI a rise of visfatin level was observed, which caused atherogenic changes in lipid profile. Inverse correlation ties have also been established between adiponectin and BMI (r = - 0,44; Р<0,05); adiponectin and HDL (r = - 0,56; Р<0,05); adiponectin and VLDL (r = - 0,44; Р<0,05 ); adiponectin and TG (r = - 0,41; Р<0,05 ) ; adiponectin and AI (r = - 0,36; Р<0,05 ) in its turn direct correlation ties have been observed between HDL and adiponectin (r = 0,38; Р<0,05 ). Demonstrated rise of visfatin and reduction of adiponectin levels are associated with the increase of amount of visceral fat and severity of obesity. The data we’ve received is consistent with the general notion about atherogenic characteristics of visfatin and its ability to aggravate metabolic disorders, including lipid exchange.

CONCLUSIONS:



  1. According to the results of our study among the patients with stable angina with concomitant obesity the level of adiponectin is 17% lower and visfatin level is 9,3 % higher in comparison to patients without obesity.

  2. Adipokine exchange dysfunction contributes to development of atherosclerosis in patients suffering from stable angina with concomitant obesity through exhaustion of antiatherogenic capabilities of adiponectine together with activation of lipid disorders with the help of visfatin, which is confirmed by the detected correlation ties.

PROSPECTS FOR FURTHER RESEARCH

A more detailed study of the role of other hormones of adipose tissue in the progression of atherosclerosis will interesting in patient with concominant obesity.



REFERENCES

  1. Babak OI, Klimenko NN. Fiziologicheskaiya I patofiziologicheskaya role adiponectina v kompleksnom regulirovanii obmena veshestv, Ukr Terap Jurnal 2010;(№ 2): 94-100

  2. Vizir VA, Berezin AE. Imunologia ateroskleroza. Znachenie biologicheskix markerov v ocenke karfiovaskyliyarnogo riska, Ukr med chasopis 2010;(№ 2): 23–36.

  3. Gorbas IM. Faktori riziky srcevo-sudinnyx zaxvoruvan: poshirenist I control Zdoroviya ukraini 2007; ( №21/1):62-63.

  4. Kovaliova OM, Asheulova TV, Ambrosova TV. Adiponectin ta leptin iak insulinosensitraizeru Praktichna angiologiya 2009;(№ 9–10):12–16.

  5. Colberg B. Jirovaiya tkan kak endokrinniy irgan Prob Endocr Patologii 2009; 55( № 1): 38–44.

  6. Kosigina AV. Gormoni jirovoi tkani – adiponectim I visvatin pri ojirenii avtoreferat Moskva, 2011:20с.

  7. Kravchun PG, Shelest OM. Markeri funkcii endoteliiy I zapalenniya u xvirox na ishemichni xvorobu serciya Medicina siogodni I zavrta 2012: №1:11с.

  8. Anghel1 SI, WahliW.Fat poetry: a kingdom for PPAR Research 2007;(17): 486—511.

  9. Kumada M, Ki'hara S, Sumitsuji S. Association of hypoadiponectinemia with coronary artery disease in men Arterioscler. Thromb.Vasc.Biol 2003;(23): 85–89.

  10. Fonseca Alaniz MH, Takada MI, Cardoso AlonsoVale J, Lima FB. Adipose tissue as an endocrine organ: from theory to practice J. Pediatr (Rio J) 2007;(83): S192—203.

УДК 616.12-009.72-056.52-008.9-092:612.018
Зміни адипокінового профілю у хворих на стабільну стенокардію та ожиріння

Габісонія Т.Н., Кравчун П.П., Паштіані Р.В.

Стаття присвячена вивченню впливу гормонів жирової тканини на розвиток атеросклерозу у хворих на стабільну стенокардію з супутнім ожирінням. Встановлено, що дисфункція адипокінового обміну сприяє розвитку гіперліпідемії та як наслідок цього прогресуванню атеросклерозу у хворих на стабільну стенокардію та ожиріння. За результатами нашого дослідження у хворих на стабільну стенокардію та ожиріння рівень адипонектину зниження на 17 % та підвищення рівня вісфатину на 9,3% у порівнянні з хворими без ожиріння.

Ключові слова: адипонектин, вісфатин, стабільна стенокардія, ожиріння, ліпідний профіль.

УДК 616.12-009.72-056.52-008.9-092:612.018



Изменения адипокинового профиляу больных стабильной стенокардией и ожирения

Габисония Т.Н., Кравчун П.П.,Паштиани Р.В.

Статья посвящена изучению влияния гормонов жировой ткани на развитие атеросклероза у больных со стабильной стенокардией и сопутствующим ожирением. Установлено, что дисфункция адипокинового обмена способствует развитию гиперлипидемии и как следствие этого прогрессированию атеросклероза у больных со стабильной стенокардией и ожирением. По результатам нашего исследования у больных стабильной стенокардией и ожирения уровень адипонектина снижение на 17% и повышение уровня висфатину на 9,3% по сравнению с больными без ожирения.

Ключевые слова: адипонектин, висфатин, стабильная стенокардия, ожирение, липидный профиль.

УДК 616.12-009.72-056.52-008.9-092:612.018


ADIPOCYTOKINE PROFILE CHANGE IN PATIENTS WITH STABLE ANGINA AND OBESITY

Gabisoniia T., Kravchun P., Pashtiani R.



The article studied the effects of adipokines in the development of atherosclerosis in patients with stable angina and concomitant obesity. Established that dysfunction adipokіnocytes exchange promotes hyperlipidemia and consequently the progression of atherosclerosis in patients with stable angina and obesity. According to the results of our study among the patients with stable angina with concomitant obesity the level of adiponectin is 17% lower and visfatin level is 9,3 % higher in comparison to patients without obesity.

Keywords: adiponectin, visfatin, stable angina, obesity, lipid profile.





Поделитесь с Вашими друзьями:


Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©azkurs.org 2019
rəhbərliyinə müraciət

    Ana səhifə